Changes in Skeletal Muscle Mass (SMM) and Measured Resting Energy Expenditure (REE) of Older Adults Following a 6-month Weight Loss Program

2020 ◽  
Vol 120 (9) ◽  
pp. A20
Author(s):  
L. Edwards ◽  
I. Puthoff ◽  
A. Bailey ◽  
M. Miller ◽  
K. Timmerman
2008 ◽  
Vol 40 (Supplement) ◽  
pp. S75
Author(s):  
Peter J. Chomentowski ◽  
John Dube ◽  
Francesca Amati ◽  
Bret H. Goodpaster

2021 ◽  
Vol 21 (1) ◽  
Author(s):  
Nana Takao ◽  
Satoshi Kurose ◽  
Takumi Miyauchi ◽  
Katsuko Onishi ◽  
Atsuko Tamanoi ◽  
...  

Abstract Background An effective strategy for weight loss in patients who are overweight or obese is to reduce body fat mass while maintaining skeletal muscle mass. Adiponectin and myostatin are affected through changes in body composition due to weight loss, and examining their dynamics may contribute to strategies for maintaining skeletal muscle mass through weight loss. We aimed to examine the relationships among myostatin, adiponectin, and body composition, depending on the extent of weight loss, in patients with obesity undergoing a weight loss program. Methods We examined 66 patients with obesity (age: 46.8 ± 14.0 years, body mass index: 34.3 [31.0–38.4] kg/m2) attending a hospital weight loss program. We categorized the patients into two groups, namely an L group (those with a weight reduction of < 5% from baseline) and an M group (those with a weight reduction of > 5% from baseline). All patients underwent blood tests and were assessed for body composition, insulin resistance, adipocytokine and myokine levels, exercise tolerance, and muscle strength at baseline and post-intervention. Results Serum myostatin and adiponectin levels increased post-intervention in both groups. Body weight and %fat decreased, and the rate of lean body mass (%LBM) increased in both groups. Exercise capacity and muscle strength improved in the M group only. Change in (⊿) myostatin correlated with ⊿%fat, ⊿%LBM, and ⊿adiponectin. ⊿adiponectin (β = − 0.262, p = 0.035) was an independent predictor of ⊿myostatin. Conclusions Myostatin and adiponectin might cross-talk and regulate changes in skeletal muscle and fat mass with or without successful weight loss. These findings indicate that evaluating serum myostatin and adiponectin levels in clinical practice could be used to predict the effects of weight loss and help prevent skeletal muscle mass loss.


2007 ◽  
Vol 21 (6) ◽  
Author(s):  
R Li ◽  
C Kerksick ◽  
B Campbell ◽  
C Wilborn ◽  
B Marcello ◽  
...  

2008 ◽  
Vol 22 (S2) ◽  
pp. 782-782
Author(s):  
M Serra ◽  
J Wismann ◽  
M Galbreath ◽  
R Chandran ◽  
K Beavers ◽  
...  

2004 ◽  
Vol 36 (Supplement) ◽  
pp. S80???S81
Author(s):  
Richard Kreider ◽  
C Rasmussen ◽  
C Kerksick ◽  
B Campbell ◽  
B Slonaker ◽  
...  

2004 ◽  
Vol 36 (Supplement) ◽  
pp. S80-S81
Author(s):  
Richard Kreider ◽  
C Rasmussen ◽  
C Kerksick ◽  
B Campbell ◽  
B Slonaker ◽  
...  

2020 ◽  
Vol 14 (Supplement_1) ◽  
pp. S191-S192
Author(s):  
D Vranesic Bender ◽  
L Cengic ◽  
D Ljubas Kelecic ◽  
I Karas ◽  
A Grbin Hodžić ◽  
...  

Abstract Background As a feature of changing phenotype of IBD in the last decade, we observe increased rates of obesity and increased BMI values as well as changes in body composition. Special interest is the impact of biological therapy on body composition and prevalence of obesity in IBD patients, since the data on this topic are limited. The aim of this study was to determine body composition and resting energy expenditure of patients treated with biological therapy. Methods The study included 74 patients (39 male and 35 female) at the Clinical Hospital Center Zagreb (52 patients with Crohn’s disease and 22 with ulcerative colitis) treated with infliximab/adalimumab/ustekinumab/vedolizumab. Resting energy expenditure was measured by the indirect calorimetry (Cosmed Quark CPET) and compared with the predicted resting energy expenditure calculated using Harris-Benedict equation. Detailed medical and nutritional anamnesis was taken and we measured the following body composition parameters using TANITA body composition analyser, BC-420MA: body mass index (BMI), fat mass (FM), visceral fat rating (VFR), muscle mass (MM) and skeletal muscle mass index (SMI) was calculated. Results Increased BMI was observed in 32% of the patients, while 41% of the whole sample had an increased FM. The mean value of skeletal muscle index (SMI) was 9,061,15 kg m−2 and it revealed the presence of moderate sarcopenia in 32 patients (43%), of which 30 were men. Indirect calorimetry (IC) obtained the value of resting energy expenditure (REE), with the measured REE (1569,81240,95 kcal) on average significantly lower than predicted (1640,36255,28 kcal), t(73)=−3.023, p &lt; 0.05. The results of this study revealed a significant prevalence of moderate sarcopenia in men, increased body mass and fat mass, and slightly lowered resting energy expenditure. There was no significant difference between body composition parameters and REE between different types of biological therapy. Conclusion The incidence of classical forms of malnutrition in this group of patients is significantly lower in comparison with standard therapy and previous experience. Most of the patients were well nourished and we observed trends toward overweight and sarcopenic obesity in some patients. A slight decrease in REE in the whole sample could be a reflection of impact of biological therapy on fat tissue and profound modulation of lipid metabolism as well as decreased muscle mass and physical activity level of the patients.


Sign in / Sign up

Export Citation Format

Share Document